Skip to main content
SpringerLink
Log in

Antihypertonika

  • Chapter
Arzneiverordnungs-Report 2018

  • 2662 Accesses

Zusammenfassung

Eine arterielle Hypertonie besteht trotz sehr guter Behandlungsmöglichkeiten in Deutschland bei einem großen Teil der Bevölkerung. Sie begünstigt das Auftreten von Apoplexie, Demenz, Herzinfarkt, Herzinsuffizienz, Nierenversagen und peripherer arterieller Verschlusskrankheit. Welche Komplikationen bei welcher Blutdruckhöhe vermehrt auftreten, ist abhängig von systolischem und diastolischem Druck und der Blutdruckamplitude (Rapso maniki et al. 2014). Bei mittelschwerer und schwerer Hypertonie ist der günstige Effekt einer konsequenten Arzneitherapie auf Morbidität und Mortalität des Hochdruckpatienten durch zahlreiche Studien belegt. In absoluten Werten ist er umso größer, je höher das kardiovaskuläre Ausgangsrisiko ist (Blood Pressure Lowering Treatment Trialists’ Collaboration 2014).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Agarwal R (2017): Implications of blood pressure measurement technique for implementation of systolic blood pressure intervention trial (SPRINT). J Am Heart Assoc 2017; 6: e004536. DOI: 10.1161/jaha.116.004536

  • Anlauf M (1994): Hypertonie im Alter. MMV Medizin Verlag, München

    Google Scholar 

  • Anlauf M, Weber F (2005): Bedeutung der Therapie mit Antihypertensiva für die kardiovaskuläre Prävention. In: Bundesärztekammer Berlin (Hrsg): Fortschritt und Fortbildung in der Medizin, Band 29, Deutscher Ärzte-Verlag, Köln

    Google Scholar 

  • Anlauf M, Weber F (2012): Neues Verfahren, aber für wen? Deutsches Ärzteblatt 109: 313

    Google Scholar 

  • Anlauf M, Weber F (2018): Blutdruckmessungen zur Hochdruckbekämpfung sollten i.d.R. mit Automaten erfolgen. Dtsch Med Wochenschr 143: 59–60

    Google Scholar 

  • Anlauf M (2013): Individualisierte Entscheidungen bei der Behandlung der Hypertonie. Arzneiverordnung in der Praxis 40: 2–4

    Google Scholar 

  • Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forciea MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA; ACCF Task Force (2011): ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 123: 2434–2506

    Google Scholar 

  • Arzneimittelkommission der Deutschen Ärzteschaft (2004): Empfehlungen zur Therapie der arteriellen Hypertonie. 2. Auflage, Arzneiverordnung in der Praxis, Band 31, Sonderheft 2 (Therapieempfehlungen), Internet: www.akdae.de/35/74_Hypertonie_2004_2Auflage.pdf

  • Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group (2008): Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358: 1887–1898

    Google Scholar 

  • Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J, McCormack T, Forette F, Gil-Extremera B, Dumitrascu D, Staessen JA, Thijs L, Fletcher A, Bulpitt C; HYVET Study Group (2011): Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 2011 Jan 4; 344: d7541

    Google Scholar 

  • Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators (2014): A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370: 1393–1401

    Google Scholar 

  • Blood Pressure Lowering Treatment Trialists’ Collaboration (2000): Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356: 1955–1964

    Google Scholar 

  • Blood Pressure Lowering Treatment Trialists’ Collaboration (2014): Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 384: 591–598

    Google Scholar 

  • Boger-Megiddo I, Heckbert SR, Weiss NS, McKnight B, Furberg CD, Wiggins KL, Delaney JA, Siscovick DS, Larson EB, Lemaitre RN, Smith NL, Rice KM, Glazer NL, Psaty BM (2010): Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. BMJ 340: c103

    Google Scholar 

  • Brown MJ (2011): Personalised medicine for hypertension. BMJ 343: d4697

    Google Scholar 

  • Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes G, Sever P, Salsbury J, Mackenzie IS, Padmanabhan S, MacDonald TM; British Hypertension Society‘s Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group (2016): Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol 4: 136–147

    Google Scholar 

  • Brunström M, Carlberg B (2018): Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure evels: A systematic review and meta-analysis. JAMA Intern Med 178: 28–36

    Google Scholar 

  • Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee (2003): The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289: 2560–2571

    Google Scholar 

  • Chow CK, Thakkar J, Bennett A, Hillis G, Burke M, Usherwood T, Vo K, Rogers K, Atkins E, Webster R, Chou M, Dehbi HM, Salam A, Patel A, Neal B, Peiris D, Krum H, Chalmers J, Nelson M, Reid CM, Woodward M, Hilmer S, Thom S, Rodgers A (2017) Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet 389: 1035–1042

    Google Scholar 

  • Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ; MOXCON Investigators (2003): Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure. Eur J Heart Fail 5: 659–667

    Google Scholar 

  • Dahlöf B, Sever PS, Neil R, Poulter NP, Wedel H (2005): Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366: 895–906

    Google Scholar 

  • Dardi F, Manes A, Palazzini M, Bachetti C, Mazzanti G, Rinaldi A, Albini A, Gotti E, Monti E, Bacchi Reggiani ML, Galiè N (2015): Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. Eur Respir J 46: 414–421

    Google Scholar 

  • Dasgupta K, Quinn RR, Zarnke KB et al (2014): The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 30: 485–501

    Google Scholar 

  • Davis BR, Piller LB, Cutler JA, Curt Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group (2006): Role of diuretics in the prevention of heart failure. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 113: 2201–2210

    Google Scholar 

  • Desch S, Okon T, Heinemann D, Kulle K, Kulle K, Röhnert K, Sonnabend M, Petzold M, Müller U, Schuler G, Eitel I, Thiele H, Lurz P (2015): Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension 65:1202–1208

    Google Scholar 

  • Deutsche Liga zur Bekämpfung des hohen Blutdrucks (2013): Leitlinien für das Management der arteriellen Hypertonie. www.hochdruckliga.de/bluthochdruck-behandlung-leitlinien.html

  • Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS (2012): Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 59: 1124–1131

    Google Scholar 

  • Elliott WJ, Meyer PM (2007): Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201–207

    Google Scholar 

  • Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K (2016): Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387: 957–967

    Google Scholar 

  • Falaschetti E, Mindell J, Knott C, Poulter N (2014): Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet 383: 1912–1919

    Google Scholar 

  • Galiè, N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group (2005): Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353: 2148–2157

    Google Scholar 

  • Galiè N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G (2008): Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371: 2093–2100

    Google Scholar 

  • Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group (2009): Tadalafil therapy for pulmonary arterial hypertension. Circulation. 119: 2894–2903

    Google Scholar 

  • Giles TD, Weber MA, Basile J, Gradman AH, Bharucha DB, Chen W, Pattathil M; NAC-MD-01 Study Investigators (2014): Efficacy and safety of nebivolol and valsartan as fixeddose combination in hypertension: a randomised, multicentre study. Lancet 383: 1889–1898

    Google Scholar 

  • Goff DC Jr, Lloyd-Jones DM, Bennett G, et al (2014): American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013. ACC/AHA guideline on the assessment of cardiovascular risk. J AmColl Cardiol 63: 2935–2959

    Google Scholar 

  • Han X, Zhang Y, Dong L, Fang L, Chai Y, Niu M, Yu Y, Liu L, Yang X, Qu S, Li S (2017): Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost. Respir Care 62: 489–496

    Google Scholar 

  • He B, Zhang F, Li X, Tang C, Lin G, Du J, Jin H (2010): Metaanalysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ J 74: 1458–1464

    Google Scholar 

  • Hopkins W, Rubin LJ (2018): Treatment of pulmonary hypertension in adults. www.uptodate.com May 02

  • Jamerson K, Weber MA, Bakris GL, Dahlöf B, Jamerson K, Weber MA, Bakris GL, Dahlöf B (2008): Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 359: 2417–2428

    Google Scholar 

  • James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E (2014): 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311: 507–520

    Google Scholar 

  • Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K; SPYRAL HTN-ON MED Trial Investigators (2018): Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 391: 2346–2355

    Google Scholar 

  • Kintscher U, Böhm M, Goss F, Kolloch R, Kreutz R, Schmieder R, Schunkert H (2014): Kommentar zur 2013-ESH/ESC-Leitlinie zum Management der arteriellen Hypertonie. Kardiologie 8: 223–230

    Google Scholar 

  • Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR; SHEP Collaborative Research Group (2005): Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95: 29–35

    Google Scholar 

  • Krämer BK, Hausberg M, Sanner B, Kusche-Vihrog K, Weil J, Weisser B, Wenzel U, Trenkwalder P; für die Task Force Wissenschaftliche Stellungnahmen und Leitlinien der DHL® (2017): Blutdruckmessung und Zielblutdruck. Stellungnahme der Deutschen Hochdruckliga e.V. DHL®/Deutsche Gesellschaft für Hypertonie und Prävention. Dtsch Med Wochenschr 142: 1446–1447

    Google Scholar 

  • Krieger EM, Drager LF, Giorgi DMA, et al. (2018): Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). Hypertension 71: 681–690

    Google Scholar 

  • Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M (2009): Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373: 1275–1281

    Google Scholar 

  • Law MR, Morris JK, Wald NJ (2009): Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338: b1665

    Google Scholar 

  • Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, et al. (2016): CHEP Guidelines Task Force. Hypertension Canada’s 2016 Canadian Hypertension Education Program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 32: 569–588

    Google Scholar 

  • Lindholm LH, Carlberg B, Samuelsson O (2005): Should betablockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366: 1545–1553

    Google Scholar 

  • Liu C, Chen J, Gao Y, Deng B, Liu K (2013): Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev; 2: CD004434

    Google Scholar 

  • Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A; European Society of Hypertension (2009): Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 27: 2121–2158

    Google Scholar 

  • Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A; Chairpersons and Section Coordinators of the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and European Society of Cardiology (ESC) (2014): Target blood pressure in elderly hypertensive patients and in patients with diabetes mellitus. J Hypertens 32: 1551–1552

    Google Scholar 

  • Mancia G, Corrao G (2018): Global Impact of the 2017 American College of Cardiology/American Heart Association Hypertension Guidelines: A Perspective From Italy. Circulation 137: 889–890

    Google Scholar 

  • Mehta S, Sastry BKS Souza R, Torbicki A, Ghofrani HA, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O (2017): Macitentan improves health-related quality of life for patients with pulmonary arterial hypertension: Results from the randomized controlled SERAPHIN trial. Chest 151: 106–118

    Google Scholar 

  • Muntner P, Carey RM, Gidding S, S, Jones DW, Taler SJ, Wright JT Jr, Whelton PK (2018): Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. Circulation 137: 109–118

    Google Scholar 

  • National Clinical Guideline Center (2011): The clinical management of primary hypertension in adults (2016 partial update). Clinical Guideline 127. Methods, evidence, and recommendations, August 2011, commissioned by the National Institute for Health and Clinical Excellence. Internet: https://www.nice.org.uk/guidance/cg127/evidence/full-guideline-pdf-8949179413

  • National Institute for Health and Care Excellence (2016): Hypertension in adults: diagnosis and management. Internet: https://www.nice.org.uk/guidance/cg127

  • Oudiz RJ, Brundage BH, Galiè N, Ghofrani HA, Simonneau G, Botros FT, Chan M, Beardsworth A, Barst RJ; PHIRST Study Group. (2012): Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol 60: 768–774

    Google Scholar 

  • Pareek AK, Messerli FH, Chandurkar NB, Dharmadhikari SK Godbole AV, Kshirsagar PP, Agarwal MA, Sharma KH, Mathur SL, Kumbla MM (2016): Efficacy of low-dose chlorthalidone and hydrochlorothiazide as assessed by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol 67: 379–389

    Google Scholar 

  • Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G; SERAPHIN Investigators (2013): Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369: 809–818

    Google Scholar 

  • Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, Hemingway H (2014): Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 383: 1899–1911

    Google Scholar 

  • Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, Redgrave JN, Bull LM, Welch SJ, Cuthbertson FC, Binney LE, Gutnikov SA, Anslow P, Banning AP, Mant D, Mehta Z; Oxford Vascular Study (2005): Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 366: 1773–1783

    Google Scholar 

  • Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR (2010a): Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 375: 895–905

    Google Scholar 

  • Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, Poulter NR, Sever PS; ASCOT-BPLA and MRC Trial Investigators (2010b): Effects of beta blockers and calciumchannel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 9: 469–480

    Google Scholar 

  • Roush GC, Holford TR, Guddati AK (2012): Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network metaanalyses. Hypertension 59: 1110–1117

    Google Scholar 

  • Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ; SUPER-2 Study Group (2011): Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 140: 1274–1283

    Google Scholar 

  • Sexton DJ, Canney M, O‘Connell MDL, Moore P, Little MA, O‘Seaghdha CM, Kenny RA (2017): Injurious falls and syncope in older community-dwelling adults meeting inclusion criteria for SPRINT. JAMA Intern Med 177: 1385–1387

    Google Scholar 

  • Sim JJ, Shi J, Kovesdy CP, Kalantar-Zadeh K, Jacobsen SJ (2014): Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol 64: 588–597

    Google Scholar 

  • Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R (2006): A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 151: 851.e1–5

    Google Scholar 

  • Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O’Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A (1997): Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350: 757–764

    Google Scholar 

  • Staessen JA, Gasowski J, Wang Lj G, Thijs L, Den Hond E, Boissel JP, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH (2000): Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355: 865–872

    Google Scholar 

  • Staessen JA, Birkenhäger WH (2005): Evidence that new anti hypertensives are superior to older drugs. Lancet 366: 869–871

    Google Scholar 

  • Strange G, Keogh AM, Williams TJ, Wlodarczyk J, McNeil KD, Gabbay E (2008): Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life. Respirology 13: 674–682

    Google Scholar 

  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2000): Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283: 1967–1975

    Google Scholar 

  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002): Major outcomes in hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288: 2981–2997

    Google Scholar 

  • The Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW (2010): A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 363: 620–628

    Google Scholar 

  • The SPRINT Research Group (2015): A randomized trial of intensive versus standard blood pressure control. N Engl J Med 373: 2103–2116

    Google Scholar 

  • The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2013): 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 31: 1281–1357

    Google Scholar 

  • Thijs L, Fagard R, Lijnen P, Staessen JA, Van Hoof R, Amery A (1992): A meta-analysis of outcome trials in elderly hypertensives. J Hypertension 10: 1103–1109

    Google Scholar 

  • Tsujimoto T, Kajio H, Shapiro MF, Sugiyama T (2018): Risk of all-cause mortality in diabetic patients taking betablockers. Mayo Clin Proc 93: 409–418

    Google Scholar 

  • Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, Norgiolini S, Bracco C, Porcellati C (2004): Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43: 963–969

    Google Scholar 

  • Vizza CD, Jansa P, Teal S, Dombi T, Zhou D. (2017): Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. BMC Cardiovasc Disord 17: 239

    Google Scholar 

  • Weber F, Anlauf M (2014): Treatment resistant hypertension – investigation and conservative management. Dtsch Arztebl Int 111: 425–431

    Google Scholar 

  • Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B (2013): Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 381: 537–545

    Google Scholar 

  • Weber MA (2015): Interpreting blood pressure in young adults. J Am Coll Cardiol 65: 336–338

    Google Scholar 

  • Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. (2018): 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 71: e13–e115

    Google Scholar 

  • Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society‘s PATHWAY Studies Group (2015): Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386: 2059–2068

    Google Scholar 

  • Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK, Caulfield MJ, Padmanabhan S, Mackenzie IS, Salsbury J, Brown MJ British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group (2018): Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 6: 464–475

    Google Scholar 

  • Williamson JD , Supiano MA , Applegate WB , Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT Jr, Pajewski NM; SPRINT Research Group (2016): Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: A randomized clinical trial. JAMA 315: 2673–2682

    Google Scholar 

  • Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, Volmink J (2007): Beta-blockers for hypertension (Review). Cochrane Database Syst Rev 2007 Jan 24; (1): CD002003

    Google Scholar 

  • Wiysonge CS, Opie LH (2013): β-Blockers as initial therapy for hypertension. JAMA 310: 1851–1852

    Google Scholar 

  • Yano Y, Stamler J, Garside DB, Daviglus ML, Franklin SS, Carnethon MR, Liu K, Greenland P, Lloyd-Jones DM (2015): Isolated systolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. J Am Coll Cardiol 65: 327–335

    Google Scholar 

  • Zhu QM, Lesnick JD, Jasper JR, MacLennan SJ, Dillon MP, Eglen RM, Blue DR (1999): Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol 126: 1522–1530

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Friedrich-Plettke-Weg 12, 27570, Bremerhaven, Deutschland

    Manfred Anlauf

  2. Thiemannstraße 18, 45219, Essen, Deutschland

    Franz Weber

Authors
  1. Manfred Anlauf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Franz Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Deutschland

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln, Deutschland

    Dieter Paffrath

  3. Arzneimittelkommission der deutschen Ärzteschaft, Herbert-Lewin-Platz 1, 10623, Berlin, Deutschland

    Wolf-Dieter Ludwig

  4. Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178, Berlin, Deutschland

    Jürgen Klauber

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Cite this chapter

Anlauf, M., Weber, F. (2018). Antihypertonika. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2018. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57386-0_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-57386-0_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-57385-3

  • Online ISBN: 978-3-662-57386-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation